Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Sponsored by Relay Therapeutics, Inc.
About this study
This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment with a CDK4/6 inhibitor.
Where this study is enrolling (6)
- Call +1 480-256-6444
Banner MD Anderson Cancer Center
Gilbert, Arizona
This research site can be reached directly by phone. Call to ask about this study.
Create a free account to get updates on similar Clinical Trials for your conditions.
- I'm interested
Atlanta Cancer Care - Northside Hospital
Atlanta, Georgia
- I'm interested
Rush University Medical Center
Chicago, Illinois
- I'm interested
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois
- Call 877-632-6789
The University of Texas M.D. Anderson Cancer Center
Houston, Texas
This research site can be reached directly by phone. Call to ask about this study.
Create a free account to get updates on similar Clinical Trials for your conditions.
Show all 6 locations
- I'm interested
Houston Methodist Hospital Cancer Center
Houston, Texas
Who can participate
Inclusion criteria
- ✓Patient has ECOG performance status of 0-1
- ✓One or more known primary oncogenic PIK3CA mutation(s)
- ✓Adult females, pre- and/or post-menopausal, and adult males. Pre-menopausal (and peri-menopausal) women can be enrolled if amenable to treatment with a gonadotropin-releasing hormone (GnRH) agonist. Patients are to have commenced treatment with a GnRH agonist at least 2 weeks prior to randomization and must be willing to continue on it for the duration of the study.
- ✓Histologically or cytologically confirmed diagnosis of HR+/HER2- locally advanced or metastatic breast cancer (ABC) with radiological or objective evidence of recurrence or progression; locally advanced disease must not be amenable to resection with curative intent
- ✓Measurable disease per RECIST v1.1 or evaluable bone-only disease.
- ✓Must have radiological evidence of progression on or after previous treatment for HR+/HER2- ABC with:
- ✓1. At least 1 and no more than 2 lines of endocrine therapy (ET) in the (neo)adjuvant setting with recurrence on or within 12 months of completion or in the ABC setting
- ✓2. Only 1 prior line of CDK4/6 inhibitor therapy in one of the following settings:
- ✓1. CDK4/6 inhibitor + ET in the ABC setting
- ✓2. CDK4/6 inhibitor therapy in the adjuvant setting if progression occurred during or within 12 months of completion of adjuvant CDK4/6 inhibitor with ET
- ✓3. Patients who progressed during or within 12 months of completion of adjuvant CDK4/6 inhibitor and after receiving CDK4/6 inhibitor therapy in the advanced setting are considered to have had \>1 prior line of CDK4/6 inhibitor and are not eligible
Exclusion criteria
- ✕Prior treatment with any of the following:
- ✕1. CDK2 inhibitors. Prior treatment with other investigational CDK inhibitors could be permitted upon discussion and approval from the Sponsor
- ✕2. PIK3, AKT, or mTOR inhibitors or any agent whose mechanism of action is the inhibit the PIK3/AKT/mTOR pathway
- ✕3. Immunotherapy
- ✕4. Antibody drug conjugates
- ✕Type 1 diabetes, or Type 2 diabetes requiring antihyperglycemic medication, or fasting plasma glucose ≥ 140 mg/dL (7.8 mmol/L), or glycosylated hemoglobin (HbA1c) ≥7.0% (≥ 53 mmol/mol).
- ✕Clinically significant, uncontrolled cardiovascular disease
- ✕Any factors that increase the risk of QTc prolongation or risk of arrhythmic events
- ✕Known active uncontrolled or symptomatic CNS metastases associated with progressive neurological symptoms or requiring ongoing corticosteroids or anticonvulsants for symptomatic control
- ✕Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease
- ✕History of hypersensitivity to fulvestrant or drugs in a similar class as fulvestrant, zovegalisib, or capivasertib, including their excipients
- ✕Known activating AKT mutations, loss-of-function PTEN mutations, or loss of PTEN expression resulting in oncogenic pathway activation downstream of PI3K
Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.